期刊文献+

卵巢上皮性癌BRCA1、p53及Ki67蛋白表达与生存时间相关性研究 被引量:3

Expression of protein BRCA1 ,p53 and Ki67 and survival analysis in epithelial ovarian cancer
下载PDF
导出
摘要 目的本研究旨在通过检测卵巢癌组织中BRCA1、p53及Ki67蛋白表达情况及其相关性;了解BRCA1、p53及Ki67的表达与患者生存时间之间的关系。方法选取50例2003年卵巢上皮性癌根治术标本,对照组为10例正常卵巢组织标本;运用PV-9000二步免疫组化法检测BRCA1、p53及Ki67蛋白的表达,以及检测其与患者生存率的关系。结果BRCA1蛋自在卵巢癌组织中表达明显增多(阳性率为88.0%,P〈0.05);BRCA1、p53及Ki67蛋白表达与患者年龄无关(P〉0.05);BRCA1、p53及Ki67蛋白之间没有明显相关性(P〉0.05);BRCA1、p53及Ki67蛋白表达与患者预后没有明显相关性(P〉0.05)。结论BRCA1蛋白在卵巢癌组织的表达量明显高于在正常卵巢组织中;BRCA1、p53、Ki67蛋白是否与患者的预后有关尚有待进一步深入研究。 Objectives To study the expression of protein BRCA1, p53 and Ki67 in epithelial ovarian cancer;To analyze the relationship between their expressions and prognosis. Methods An immunohistochemistry was performed on samples from 50 epithelial ovarian cancer. Results The expression of protein BRCA1 in ovarian cancer is much higher than that in the normal tissues ( expression rate 88.0% , P 〈 0.05 ) ; The expression of protein BRCA1, p53 and Ki67 are not correlated with each other(P 〉 0.05 ) ; The expression of protein BRCA1, p53 and Ki67 are not associated with ages (P 〉 0.05 ) ;The Kaplan Meier survival analysis shows that the survivals among the three proteins have no significance ( P 〉 0.05 ). Conclusion Overexpression of BRCA1 is much more significant for than ovarian cancer that of normal ovarian tissues. BRCA1, p.53 and Ki67 might be used to predict the prognosis of ovarian cancer.
出处 《实用肿瘤学杂志》 CAS 2009年第2期134-138,共5页 Practical Oncology Journal
关键词 卵巢癌 BRCA1 P53 KI67 免疫组化 生存分析 BRCA1 p53 Ki67 Immunohistochemsitry Surviaval analysis
  • 相关文献

参考文献19

  • 1Miki Y, Swensen J, Shattuck ED, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 [ J]. Science, 1994,266 (5182) :66 - 71.
  • 2Ford D. Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [ J ]. Am J Hum Genet, 1998,62 : 676 - 689.
  • 3Gretarsdottir S, Thorlacius S, Valgardsdottir R, et al. BRCA2 and p53 mutation in primary breast cancer in relation to genetic instability [ J ]. Cancer Research, 1998,58 (5) :859.
  • 4Milner B J, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma [ J ]. Cancer Res. 1993.53:2128 - 2132.
  • 5Soslow RA, Shen PU, Chung MH, et al. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma[ J]. Int J Gynecol Pathol, 1998,17 : 129 - 134.
  • 6Gras E, Cortes J, Diez O, et al. Loss of heterozygosity on chromosome 13q12 - q14, BRCA - 2 mutations and tack of BRCA- 2 promoter hypermethylation in sporadic epithelial ovarian tumors [ J ]. Cancer,2001,92:787 - 795.
  • 7Koul A, Malander S, Loman N,et al. BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features[ J]. Int J Gyneeol Cancer,2000,10:289 - 295.
  • 8Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer[ J]. Int J Gynecol Pathol,2002,21:407 - 411.
  • 9吴育连,彭淑牖,沈宏伟.人类胰腺癌Ki-67基因表达的研究[J].中华外科杂志,1998,36(12):732-734. 被引量:6
  • 10Chey Y, Chen CF, Riley D J, et al. Aberrant subcelluar localization of BRCA1 in breast cancer [ J ]. Science, 1995, 270:789 - 791.

二级参考文献10

  • 1李静,刘文清,范丽萍,徐彤,黄湛.结肠癌P53蛋白表达与临床病理的意义[J].韶关学院学报,2006,27(3):87-88. 被引量:5
  • 2狄建忠,郑起,赵中辛,樊友本,汪昱,史亚洲.P57^(kip2)与Ki67表达对结肠癌侵袭性的影响[J].肿瘤,2006,26(8):765-767. 被引量:6
  • 3Somasundaram K. Tumor suppressor p53: regulation and function [ J ]. Front Biosci, 2000,5:424-437.
  • 4Forones NM, Oshima C, Nanogaki S , et al. Determination of proliferative activity using ki67 and expression of p53 in colorectal cancer [ J ]. Arq Gastroenterol, 1999,36 : 122.
  • 5Schumaehcr U, Adam E, Fedhaus S, et al. Cell differention and chemosterapy influence p53 and MDM2 immunoreactivity in, human HT29 colon carcer cells grown in scid mice [ J]. Cancer Lett , 2001,166(2) :215-221.
  • 6Kem P,Painer M,Raiha I,et al.A marked increase in the incidence of colorectal cancer over two decades in southwest Finland[J].Clin Epidemiol,1997,50 (2):147-151.
  • 7Ikenaga M,Takano Y,Obtain Y,et al.Low levels of apoptosis and proliferative activity in colorectal villous tumors:Comparation with tubular tumors[J].Pathol Int,1998,48 (6),453-458.
  • 8Forones NM,Oshima C,Nanogaki S,et al.Determination of proliferative activity using Ki67 and expression of p53 in colorectal cancer[J].Arq Gastroenterol,1999,36 (3):122-126.
  • 9Rau B,Sturm I,Lage H,et al.Dynamic expression profile of P21WAF1/CIPland Ki67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy[J].Clin Onool,2003,21 (18):3391-3401.
  • 10Ben-Izhak O,Bar-Chana M,Sussman L,et al.Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma[J].stopathology,2002,41 (6):519-525.

共引文献21

同被引文献27

  • 1李红敏,许青霞,孙萍.血清CA125检测对卵巢癌诊断的意义[J].肿瘤基础与临床,2007,20(5):405-406. 被引量:21
  • 2Therasse P;Arbuck SG;Eisenhauer EA.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada,2000.
  • 3Robertson DM, Pruysers E, Jobling T. Inhibin as a diagnostic marker for ovarian cancer [J]. Cancer Lett, 2007, 249 (1) : 14-17.
  • 4Tut VM, Braithwaite KL, Angus B, et al. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, wall, pRb and Ki67 [J]. Br J Cancer, 2001, 84 (2) : 270-275.
  • 5Medeiros LR, Rosa DD, da Rosa MI. Accuracy of CA 125 in the diagnosis of owtrian tumors: a quantitative systematic review [J]. Eur J ()bstet Gynecol Reprod Biol, 2009, 142 (2) : 99-105.
  • 6Rocconi RP, Matthews KS, Kemper MK, et al. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer [J]. Gynecol Oncol, 2009,114( 2 242-245.
  • 7Agarwal R, Kaye SB. Expression profiling and individualisation of treatment for ovarian cancer [J]. Curr Opin Pharmacol, 2006, 6 ( 4 ) : 345-349.
  • 8JemalA,Siegel R,XuJ. Cancer statistics,2010[J].CA:A Cancer Journal for Clinicians,2010,(05):277-300.
  • 9Ecke TH,Schlechte HH,Schiemenz K. TP53 gene mutations in prostate cancer progression[J].Anticancer Research,2010,(05):1579-1586.
  • 10Baker L,Quinlan PR,Patten N. p53 mutation,deprivation and poor prognosis in primary breast cancer[J].British Journal of Cancer,2010,(04):719-726.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部